SeaStar Medical Welcomes Stanford Medicine's Enrollment in AKI Trial
SeaStar Medical Holding Corporation (NASDAQ: ICU) is excited to announce that Stanford Medicine will begin actively enrolling subjects in its pivotal trial focused on Adult Acute Kidney Injury (AKI). This collaboration emphasizes the company’s mission to enhance treatment options for patients experiencing severe inflammation affecting vital organs.
Significance of Stanford Medicine in the Trial
According to Kevin Chung, MD, Chief Medical Officer of SeaStar Medical, having Stanford onboard is monumental. The recent policy change by the U.S. Centers for Medicare and Medicaid Services (CMS) facilitating reimbursements for certain expenses related to Medicare patients plays a crucial role in expanding recruitment for this trial.
Recruitment and Trial Expansion
With the addition of two Department of Defense medical centers, the NEUTRALIZE-AKI trial now includes 12 activated sites capable of enrolling participants. The total patient recruitment has reached 52, illustrating the growing interest and importance of this study in the medical community.
Overview of the NEUTRALIZE-AKI Pivotal Trial
The NEUTRALIZE-AKI trial focuses on assessing the safety and effectiveness of the Selective Cytopheretic Device (SCD) developed by SeaStar Medical. This innovative device recently received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for treating adults with AKI.
Trial Design and Goals
The clinical trial will target a maximum enrollment of 200 adult subjects suffering from AKI while receiving continuous kidney replacement therapy (CKRT) in intensive care settings. The primary goal is to examine the impact of the SCD on 90-day mortality rates and dialysis dependency against a control group receiving only standard CKRT care.
Understanding Acute Kidney Injury (AKI)
AKI is marked by a rapid and often temporary decline in kidney function due to various medical conditions, including infections, trauma, or surgical complications. It can lead to hyperinflammation which exacerbates the condition and can damage other organs.
Complications from Hyperinflammation
The response of heightened inflammation can lead to severe consequences such as multi-organ dysfunction or failure, further complicating recovery. Recognizing the link between hyperinflammation and AKI highlights the need for targeted therapeutic interventions.
Innovative Solutions: Selective Cytopheretic Device (SCD)
SeaStar's proprietary SCD technology operates by precisely targeting inflammatory cells to mitigate the inflammatory response during CKRT. This revolutionary approach aims not only to improve patient outcomes but also to minimize the long-term need for dialysis or kidney replacement therapy.
Commercialization of Pediatric Device QUELIMMUNE™
The company is also excited about the progress of its pediatric variant, QUELIMMUNE™, which has been cleared for use in critically ill children weighing ten kilograms or more. This device received FDA approval under a Humanitarian Device Exemption, attesting to its significance in the pediatric field.
About SeaStar Medical
SeaStar Medical is a pioneering medical technology firm dedicated to transforming how extracorporeal therapies address the detrimental effects of inflammation in critically ill patients. By focusing on progressive and scientifically backed solutions, they continue to provide promising interventions in the field of medicine.
For more information about SeaStar Medical and its innovative therapies, interested parties are invited to visit their official website or explore their updates on LinkedIn and social media platforms.
Frequently Asked Questions
What is the NEUTRALIZE-AKI trial?
The NEUTRALIZE-AKI trial evaluates the safety and efficacy of SeaStar Medical's Selective Cytopheretic Device for adults with acute kidney injury.
Why is Stanford Medicine important for this trial?
Stanford Medicine is a key site for patient enrollment, enhancing the trial's credibility and outreach to a critical patient population.
What is the goal of the Selective Cytopheretic Device?
The SCD aims to reduce hyperinflammation in AKI patients, potentially improving outcomes and decreasing the need for dialysis.
How does AKI affect patients?
AKI leads to a sudden loss of kidney function, risking severe complications including multi-organ failure and elevated healthcare costs.
What recent developments have impacted this trial?
A decision by CMS to reimburse medical expenses for Medicare patients has significantly facilitated the recruitment of additional trial sites.
